PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
Abstract
Objective: to calculate cost difference between two approaches for immunosuppressive therapy after renal transplantation: everolimus plus reducedexposure cyclosporine and mycophenolic acid plus standard-exposure cyclosporine. Methods. We calculated the two-year difference in costs that resulted from effectiveness and safety differences of alternatives employing the probability-statistical model. Data on safety and efficiency were taken from D. Cibrik et al. (2013) randomized control trial. We also estimated the budget impact for everolimus inclusion into 7 expensive diseases program (7EDP). 7 EDP is the special federal program of drug provision for patients suffering from 7 certain diseases and health states including organ posttransplantation period. Results. Everolimus plus reduced-exposure cyclosporine leads to cost reduction by 161 RUB thousands (17%) per patient in a two-year period. The reduction mainly results from cheaper medication in everolimus plus reduced-exposure cyclosporine approach compared to mycophenolic acid plus standard-exposure cyclosporine. Everolimus inclusion into 7 expensive diseases program leads to reduction in federal budget spending starting from the first year; the total five-year budget savings are 275 RUB millions.
About the Authors
M. V. Avxentyeva
Russian Presidential Academy of National Economy and Public Administration, Moscow;
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow;
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
Avxentyeva Maria Vladimirovna – PHD (doctor of medical sciences), leading research fellow of Laboratory for health technology assessment of Applied economic research Institute of Russian academy of national economy and public administration, leading research fellow of Centre for health finance of Research Financial institution of Ministry of Finance and professor of High school of healthcare management of the First Moscow state medical university named after I.M. Sechenov. Address: Vernadskogo prospect, 82-1, Moscow, 119571, Russia, RANEPA IPEI, Laboratory for health technology assessment. Tel.: +74999569528, +74999569529. E-mail: avksent@yahoo.com.
N. A. Avxentyev
Russian Presidential Academy of National Economy and Public Administration, Moscow;
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow;
Russian Federation
Russian Federation
Avxentyev Nikolay Alexandrovich – research fellow of Centre for regional reforms research of Applied economic research Instituteof Russianacademy of national economy and public administration and junior research fellow of Centre for perspective financial planning, macroeconomic analysis and financial statistics of Research Financial institution of Ministry of Finance. Address: Nastasyinsky per., 3-2, Moscow, 127006, Russia. Tel.: +74956997414; E-mail: na@nifi.ru.
M. Yu. Frolov
Volgograd State Medical University
Russian Federation
Russian Federation
Frolov Maxim Yurievich – PHD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department of Volgogradstate medical university. Address: Pavshih borzov pl., 1, Volgograd, 400131, Russia. Tel.: +79023831020. E-mail: mufrolov66@gmail.com.
E. V. Derkach
Russian Presidential Academy of National Economy and Public Administration, Moscow;
National Center for Technology Assessment in Health Care, Moscow
Russian Federation
Russian Federation
Derkach Elena Vladimirovna – PHD (candidate of medical sciences), leading research fellow of Laboratory for health technology assessment of Applied economic research Institute of Russian academy of national economy and public administration. Address: Vernadskogo prospect, 82-1,Moscow, 119571,Russia. RANEPA IPEI, Laboratory for health technology assessment. Tel.: +74999569528, +74999569529. E-mail: evd@hta-rus.ru.
References
1. Bikbov B.T., Tomilina N.A. Replacement therapy in patients with chronic renal insufficiency methods of peritoneal dialysis and kidney transplantation in the Russian Federation in 1998-2011, the (Report to the Russian Register of renal replacement therapy. Part Two). Nephrology and Dialysis [Zamestitel’naya terapiya bol’nykh s khronicheskoi pochechnoi nedostatochnost’yu metodami peritoneal’nogo dializa i transplantatsii pochki v Rossiiskoi Federatsii v 1998-2011 g. (Otchet po dannym Rossiiskogo registra zamestitel’noi pochechnoi terapii. Chast’ vtoraya). Nefrologiya i dializ]. 2014; 192-227.
2. Instructions for use of the drug Timoglobulin [Instruktsiya po primeneniyu lekarstvennogo preparata Timoglobulin]. http://www.rlsnet.ru/tn_index_id_3138.htm .
3. Clinical Recommendations for diagnosis, treatment and prevention of infectious complications in patients with transplanted kidney / AV Vatazin, SV Gauthier, JG Moysyuk, EI Prokopenko, VE Sjutkin, NA Tomilina [Klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike infektsionnykh oslozhnenii u patsientov s transplantirovannoi pochkoi / A.V. Vatazin, S.V. Got'e, Ya.G. Moisyuk, E.I. Prokopenko, V.E. Syutkin, N.A. Tomilina]. http://nonr.ru/?page_id=3126.
4. Kulikov A.Yu. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology / FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2008; 1: 12-17.
5. Letter from the Ministry of Health of Russia 15.12.2014 N 11.9 / 10 / 2-9454 «On the methods of payment of medical assistance provided under the program of state guarantees of free provision of medical care to citizens» (with the «Guidelines on how to pay for medical care at the expense of compulsory health insurance «) [Pis'mo Minzdrava Rossii ot 15.12.2014 N 11.9/10/2-9454 «O sposobakh oplaty meditsinskoi pomoshchi, okazannoi v ramkakh programmy gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi» (vmeste s «Metodicheskimi rekomendatsiyami po sposobam oplaty meditsinskoi pomoshchi za schet sredstv obyazatel'nogo meditsinskogo strakhovaniya»)].
6. Government Decree of 28.11.2014 №1273 «On the Program of the state guarantees the free provision of medical care to citizens for 2015 and the planning period of 2016 and 2017» [Postanovlenie Pravitel'stva RF ot 28.11.2014 №1273 «O Programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2015 god i na planovyi period 2016 i 2017 godov»].
7. Order of the Ministry of Health of the Russian Federation of December 28, 2012 №1575n «On approval of the standard of primary health care in the presence of transplanted kidneys» [Prikaz Ministerstva zdravookhraneniya RF ot 28 dekabrya 2012 g. №1575n «Ob utverzhdenii standarta pervichnoi mediko-sanitarnoi pomoshchi pri nalichii transplantirovannoi pochki»].
8. Order of the Government of the Russian Federation of December 30, 2014 № 2782r «On approving the list of vital and essential medicines in 2015, as well as lists of drugs for medical use and a minimum range of medicines required for medical care» [Rasporyazhenie Pravitel'stva RF ot 30 dekabrya 2014 g. № 2782r «Ob utverzhdenii perechnya zhiznenno neobkhodimykh i vazhneishikh lekarstvennykh preparatov na 2015 god, a takzhe perechnei lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal'nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoi pomoshchi»].
9. Kidney transplantation. National clinical guidelines. Russian public organization transplant «Russian transplantologicheskoe society» [Transplantatsiya pochki. Natsional'nye klinicheskie rekomendatsii. Obshcherossiiskaya obshchestvennaya organizatsiya transplantologov «Rossiiskoe transplantologicheskoe obshchestvo»]. 2013; 50 s.
10. Chapman J.R. Chronic calcineurin inhibitor nephrotoxicity – lest we forget. Am J Transplant. 2011; 11 (4): 693-697.
11. Cibrik D., Tedesco Silva H. Jr., Vathsala A., Lackova E. et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013; 95: 933-942.
12. Ferté C., Paci A., Zizi M., Gonzales D.B. et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. European Journal of Cancer. 2011; 47 (15): 2249-2255.
13. Gondos A., Döhler B., Brenner H., Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013; 95 (2): 267-274.
14. Humar A., Limaye A.P., Blumberg E.A. et al. Extended valganciclovir prophylaxis in D+/Rkidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: twoyear results of the IMPACT study. Transplantation. 2010; 90: 1427.
15. Kaplan B., Qazi Y., Wellen J.R. Strategies for the management of adverse events associated with mTOR inhibitors. Transplantation reviews (Orlando, Fla.). 2014; 28 (3): 126-133.
16. Karam G. Kälble T., Alcaraz A., Aki F.T. et al. Guidelines on Renal Transplantation. European Association of Urology. 2014.
17. Kurtkoti J., Sakhuja V., Sud K., Minz M. et al. The Utility of 1and 3-Month Protocol Biopsies on Renal Allograft Function: A Randomized Controlled Study. American Journal of Transplantation. 2008; 8: 317-323.
18. Mahé E., Morelon E., Lechaton S. et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005; 79: 476-482.
19. Morales J.M., Marcén R., del Castillo D. et al. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant. 2012; 27 (4): 39-46.
20. Tedesco Silva H. Jr., Cibrik D., Johnston T., Lackova E. et al. Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients. American Journal of Transplantation. 2010; 10: 1401-1413
For citation:
Avxentyeva M.V., Avxentyev N.A., Frolov M.Yu., Derkach E.V. PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2015;8(1):7-17. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.1.007-017
Views: 921
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 